ロード中...
Edaravone Injected at the Start of Reperfusion Suppresses Myonephropathic Metabolic Syndrome in Rats
The purpose of this study was to evaluate whether edaravone (Radicut(®), Mitsubishi Tanabe Pharma Co., Osaka, Japan) injected at the start of reperfusion can suppress myonephropathic-metabolic syndrome (MNMS). MNMS models were made by clamping the bilateral common femoral arteries for 5 hours. At de...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Thieme Medical Publishers
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4169098/ https://ncbi.nlm.nih.gov/pubmed/25317032 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1055/s-0034-1387825 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|